NEXT-GENERATION DIAGNOSTICS IN ACUTE LYMPHOBLASTIC LEUKEMIA: FROM ULTRA-SENSITIVE MEASURABLE RESIDUAL DISEASE TO ARTIFICIAL INTELLIGENCE (2020–2026)
Objectives: Acute lymphoblastic leukemia (ALL) diagnostics have changed rapidly in recent years, moving beyond conventional morphology, flow cytometry, and targeted molecular testing toward ultra-sensitive measurable residual disease (MRD) assays, genome-wide profiling, and artificial intelligence (AI). This review exa...